207 related articles for article (PubMed ID: 11054674)
1. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines.
Nagy N; Cerboni C; Mattsson K; Maeda A; Gogolák P; Sümegi J; Lányi A; Székely L; Carbone E; Klein G; Klein E
Int J Cancer; 2000 Nov; 88(3):439-47. PubMed ID: 11054674
[TBL] [Abstract][Full Text] [Related]
2. Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines.
Kis LL; Nagy N; Klein G; Klein E
Int J Cancer; 2003 May; 104(5):658-61. PubMed ID: 12594824
[TBL] [Abstract][Full Text] [Related]
3. The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells.
Nagy N; Mattsson K; Maeda A; Liu A; Székely L; Klein E
Immunol Lett; 2002 Jun; 82(1-2):141-7. PubMed ID: 12008045
[TBL] [Abstract][Full Text] [Related]
4. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
Nagy N; Maeda A; Bandobashi K; Kis LL; Nishikawa J; Trivedi P; Faggioni A; Klein G; Klein E
Int J Cancer; 2002 Aug; 100(4):433-40. PubMed ID: 12115526
[TBL] [Abstract][Full Text] [Related]
5. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A.
Shlapatska LM; Mikhalap SV; Berdova AG; Zelensky OM; Yun TJ; Nichols KE; Clark EA; Sidorenko SP
J Immunol; 2001 May; 166(9):5480-7. PubMed ID: 11313386
[TBL] [Abstract][Full Text] [Related]
6. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4.
Sayós J; Nguyen KB; Wu C; Stepp SE; Howie D; Schatzle JD; Kumar V; Biron CA; Terhorst C
Int Immunol; 2000 Dec; 12(12):1749-57. PubMed ID: 11099315
[TBL] [Abstract][Full Text] [Related]
7. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
Parolini S; Bottino C; Falco M; Augugliaro R; Giliani S; Franceschini R; Ochs HD; Wolf H; Bonnefoy JY; Biassoni R; Moretta L; Notarangelo LD; Moretta A
J Exp Med; 2000 Aug; 192(3):337-46. PubMed ID: 10934222
[TBL] [Abstract][Full Text] [Related]
8. Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family.
Lewis J; Eiben LJ; Nelson DL; Cohen JI; Nichols KE; Ochs HD; Notarangelo LD; Duckett CS
Clin Immunol; 2001 Jul; 100(1):15-23. PubMed ID: 11414741
[TBL] [Abstract][Full Text] [Related]
9. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A.
Li SC; Gish G; Yang D; Coffey AJ; Forman-Kay JD; Ernberg I; Kay LE; Pawson T
Curr Biol; 1999 Dec; 9(23):1355-62. PubMed ID: 10607564
[TBL] [Abstract][Full Text] [Related]
10. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome.
Tangye SG; Phillips JH; Lanier LL; Nichols KE
J Immunol; 2000 Sep; 165(6):2932-6. PubMed ID: 10975798
[TBL] [Abstract][Full Text] [Related]
11. X-linked lymphoproliferative disease: a progressive immunodeficiency.
Morra M; Howie D; Grande MS; Sayos J; Wang N; Wu C; Engel P; Terhorst C
Annu Rev Immunol; 2001; 19():657-82. PubMed ID: 11244050
[TBL] [Abstract][Full Text] [Related]
12. [X-linked lymphoproliferative syndrome, EBV virus infection and defects in cytotoxicity lymphocyte regulation].
Malbrán A; Belmonte L; Ruibal-Ares B; Baré P; Bracco MM
Medicina (B Aires); 2003; 63(1):70-6. PubMed ID: 12673966
[TBL] [Abstract][Full Text] [Related]
13. Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients.
Ferrand V; Li C; Romeo G; Yin L
J Med Virol; 2003 May; 70(1):131-6. PubMed ID: 12629654
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease.
Erdõs M; Uzvölgyi E; Nemes Z; Török O; Rákóczi E; Went-Sümegi N; Sümegi J; Maródi L
Hum Mutat; 2005 May; 25(5):506. PubMed ID: 15841490
[TBL] [Abstract][Full Text] [Related]
15. A "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome.
Hwang PM; Li C; Morra M; Lillywhite J; Muhandiram DR; Gertler F; Terhorst C; Kay LE; Pawson T; Forman-Kay JD; Li SC
EMBO J; 2002 Feb; 21(3):314-23. PubMed ID: 11823424
[TBL] [Abstract][Full Text] [Related]
16. X-linked lymphoproliferative disease is caused by deficiency of a novel SH2 domain-containing signal transduction adaptor protein.
Schuster V; Kreth HW
Immunol Rev; 2000 Dec; 178():21-8. PubMed ID: 11213803
[TBL] [Abstract][Full Text] [Related]
17. Molecular and immunological basis of X-linked lymphoproliferative disease.
Latour S; Veillette A
Immunol Rev; 2003 Apr; 192():212-24. PubMed ID: 12670406
[TBL] [Abstract][Full Text] [Related]
18. Dual functional roles for the X-linked lymphoproliferative syndrome gene product SAP/SH2D1A in signaling through the signaling lymphocyte activation molecule (SLAM) family of immune receptors.
Li C; Iosef C; Jia CY; Han VK; Li SS
J Biol Chem; 2003 Feb; 278(6):3852-9. PubMed ID: 12458214
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells.
Morra M; Lu J; Poy F; Martin M; Sayos J; Calpe S; Gullo C; Howie D; Rietdijk S; Thompson A; Coyle AJ; Denny C; Yaffe MB; Engel P; Eck MJ; Terhorst C
EMBO J; 2001 Nov; 20(21):5840-52. PubMed ID: 11689425
[TBL] [Abstract][Full Text] [Related]
20. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses.
Sumegi J; Seemayer TA; Huang D; Davis JR; Morra M; Gross TG; Yin L; Romco G; Klein E; Terhorst C; Lanyi A
Leuk Lymphoma; 2002 Jun; 43(6):1189-201. PubMed ID: 12152986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
